Acrivon Therapeutics annual current ratio
2021
2022
2023
2024
2025
Acrivon Therapeutics Current Ratio Growth & History (ACRV)
Acrivon Therapeutics's current ratio was 7.69 for fiscal 2025.
View full Acrivon Therapeutics company overviewAcrivon Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 7.69 | −2.86 | −27.12% |
| 2024 | 2024-12-31 | 10.55 | 0.80 | +8.23% |
| 2023 | 2023-12-31 | 9.75 | −10.52 | −51.91% |
| 2022 | 2022-12-31 | 20.27 | −14.18 | −41.17% |
| 2021 | 2021-12-31 | 34.46 | — | — |
Acrivon Therapeutics quarterly current ratio
Q4.21
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 7.99 | −2.31 | −22.44% |
| Q1 2026 | 2026-03-31 | 8.98 | −2.19 | −19.63% |
| Q4 2025 | 2025-12-31 | 7.69 | −2.86 | −27.12% |
| Q3 2025 | 2025-09-30 | 8.75 | −4.00 | −31.35% |
| Q2 2025 | 2025-06-30 | 10.31 | −5.86 | −36.23% |
| Q1 2025 | 2025-03-31 | 11.17 | −1.24 | −9.96% |
| Q4 2024 | 2024-12-31 | 10.55 | 0.80 | +8.23% |
| Q3 2024 | 2024-09-30 | 12.75 | −2.79 | −17.93% |
| Q2 2024 | 2024-06-30 | 16.16 | −5.68 | −26.02% |
| Q1 2024 | 2024-03-31 | 12.40 | −9.41 | −43.15% |
| Q4 2023 | 2023-12-31 | 9.75 | −10.52 | −51.91% |
| Q3 2023 | 2023-09-30 | 15.54 | 3.23 | +26.23% |
| Q2 2023 | 2023-06-30 | 21.84 | — | — |
| Q1 2023 | 2023-03-31 | 21.82 | — | — |
| Q4 2022 | 2022-12-31 | 20.27 | −14.18 | −41.17% |
| Q3 2022 | 2022-09-30 | 12.31 | — | — |
| Q4 2021 | 2021-12-31 | 34.46 | — | — |
Acrivon Therapeutics current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Acrivon Therapeutics's current ratio decreased from 34.46 to 7.69, a change of −26.77. The latest reported quarter, Q2 2026, shows 7.99.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acrivon Therapeutics source filings ↗